Efficacy of Tezepelumab in Peanut Oral Immunotherapy

The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 periods: (i) a monotherapy period comprised of injections of either Tezepelumab or placebo from week 0 to week 8, (ii) followed by a combination therapy period comprised of 56 weeks during which peanut OIT is built up and maintained, and (iii) a treatment withdrawal period comprised of 12 weeks. This study will enroll 62 peanut-allergic individuals from 12 to 55 years of age who experience dose-limiting symptoms to \<=100 mg of peanut protein in a single dose (\<= 144 mg cumulative dose) as assessed by DBPCFC. The primary objective is to determine whether 56 weeks of tezepelumab plus peanut OIT as compared to 56 weeks of placebo plus peanut OIT induces sustained unresponsiveness to peanut 12 weeks after stopping combination therapy.

NCT Number	NCT07015996
Lead Sponsor	National Institute of Allergy and Infectious Diseases (NIAID) Collaborators: Immune Tolerance Network (ITN), PPD Development, LP, Rho Federal Systems Division, Inc.
Conditions	Peanut Allergy
Enrollment	62 participants
Start Date	2026-07-15
Primary Completion	2028-09-16 (estimated)
Study Completion	2028-09-16 (estimated)
Updated on ClinicalTrials.gov	2026-06-26